Answers are grounded in this paper and cite their sources.
Background: Sickle cell-beta thalassemia (HbS/-thal) is a good example of a mixture of two types of common hereditary anemias in the Middle East and Mediterranean area, and lately throughout the world (because of continuous people movement to different parts of the globe especially western countries).Since iron Overload is blamed for most of complications encountered in these patients, it is very important tochelate them effectively and safely, and deferasirox is one of the best approved options up to date. Objective:To find out the effects of (deferasirox) within these patients on serum ferritn, functions of liver and kidney, platelet count, and major side events. Type of the study: Retrospective. Methods:This is aretrospective extension study for 24 months of 23 (out of a total 52) patients suffering from sickle cell-beta thalassemia (HbS/-thal) whom regularly attending Baghdad Hereditary Anemia Center at Ibn Albaladi Hospital for their usual medical care. Medical records of those patients were evaluated regarding five major arms including serum ferritin levels (measured every 3 months), liver enzyme alanine aminotransferase (ALT), serum creatinine, platelets count, and major adverse events (all were evaluated on monthly intervals). At the baseline, all the involved patients were 2 years old, their serum ferritin levels more than one thousand g/L, with normal kidney function measured through serum creatinine, normal platelets count, normal heart function considered by 50% echocardiographic left ventricular ejection fraction (LVEF), and alanine aminotransferase (ALT) levels were less than 5 times the upper normal laboratory limit. These limitations led to the exclusion of 29 patients from being enrolled, leaving 23 patients on the table of this study. Patients were divided into two bands namelychelation nave group andpreviously chelated with deferoxamin. Period of data collection started from 2 nd of January 2014 till the 1 st of January 2016. Results:Total patients encountered were 23, 13 of them were males (57%) and the rest (43%) were females as they were 10 patients.All five arms evaluated showed varying degrees of response in reaction to deferasirox treatment, serum ferritin levels decreased progressively and a bit faster in the first year, serum creatinine lowered steadily with less values in chelation nave group of patients, serum alanine aminotransferase (ALT) had an evanescent rise at the starting months, that declined later on. Platelet counts were lower in previously chelated group expressing a gradual increase for both groups of patients.Nausea &/or vomiting were the most frequently faced side effects, and most of them were temporary occurred during the start of treatment and faded away with time either spontaneously or by medical interventions. All these effects were more seen within previously chelated set of patients. Conclusions: After a completed 24 months of evaluation, (deferasirox)has the abilityto decrease iron overload insusceptible patients whatever was their previous chelation status.
No takes yet. Share an insight, caveat, or question.
Hayder Al-Momen (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: